Disentangling the Ultrafiltration rate-mortality association: The respective roles of session length and weight gain

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 7, 2013, Pages 1151-1161

  Flythe, Jennifer E ^a,b   Curhan, Gary C ^a,b   Brunelli, Steven M ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DAVITA CLINICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; COMORBIDITY; CONTROLLED STUDY; DEATH; EXPOSURE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; NEPHROLOGIST; OUTCOME ASSESSMENT; SURVIVAL TIME; ULTRAFILTRATION; WEIGHT GAIN;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UREA; WEIGHT GAIN;

EID: 84879836245     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09460912     Document Type: Article

References (32)

1. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004.
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 [Suppl 3]: S112-S119, 1998.
3. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS. Kidney Int 69: 1222-1228, 2006.
4. Movilli E, Gaggia P, Zubani R, Camerini C, Vizzardi V, Parrinello G, Savoldi S, Fischer MS, Londrino F, Cancarini G: Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant 22: 3547-3552, 2007.
5. Flythe JE, Kimmel SE, Brunelli SM: Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int 79: 250-257, 2011.
6. Curatola G, Bolignano D, Rastelli S, Caridi G, Tripepi R, Tripepi G, Politi R, Catalano F, Delfino D, Ciccarelli M, Mallamaci F, Zoccali C: Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events. J Nephrol 24: 465-473, 2011.
7. Kimmel PL, Varela MP, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Amarashinge A, Mishkin GJ, Cruz I, Veis JH: Interdialyticweight gain and survival in hemodialysis patients: Effects of duration of ESRD and diabetes mellitus. Kidney Int 57: 1141-1151, 2000.
8. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC: Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 119: 671-679, 2009.
9. Stegmayr BG, Brannstrom M, Bucht S, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Holmberg B, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Lundstrom O, Mikaelsson L, Mortzell M, Olausson E, Persson B, Svensson L, Wikdahl AM: Minimized weight gain between hemodialysis contributes to a reduced risk of death. Int J Artif Organs 29: 675-680, 2006.
10. Holmberg B, Stegmayr BG: Cardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gain. Hemodial Int 13: 27-31, 2009.
11. Brunelli SM, Chertow GM, Ankers ED, Lowrie EG, Thadhani R: Shorter dialysis times are associated with highermortality among incident hemodialysis patients. Kidney Int 77: 630-636, 2010.
12. Marshall MR, Byrne BG, Kerr PG, McDonald SP: Associations of hemodialysis dose and session length with mortality risk in Australian andNewZealand patients. Kidney Int 69: 1229-1236, 2006.
13. Lowrie EG, Li Z, Ofsthun N, Lazarus JM: Measurement of dialyzer clearance, dialysis time, and body size: Death risk relationships among patients. Kidney Int 66: 2077-2084, 2004.
14. Flythe JE, Curhan GC, Brunelli SM: Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 83: 104-113, 2013.
15. Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysisinduced cardiac injury: Determinants and associated outcomes. Clin J Am Soc Nephrol 4: 914-920, 2009.
16. Flythe JE, Kunaparaju S, Dinesh K, Cape K, Feldman HI, Brunelli SM: Factors associated with intradialytic systolic blood pressure variability. Am J Kidney Dis 59: 409-418, 2012.
17. Shivalkar B, Flameng W, Szilard M, Pislaru S, Borgers M, Vanhaecke J: Repeated stunning precedes myocardial hibernation in progressive multiple coronary artery obstruction. J Am Coll Cardiol 34: 2126-2136, 1999.
18. Ritz E, Wanner C: The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 3: 920-929, 2008.
19. Törnig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G: Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7: 667-675, 1996.
20. Chen PS, Chou CC, Tan AY, Zhou S, Fishbein MC, Hwang C, Karagueuzian HS, Lin SF: The mechanisms of atrial fibrillation. J Cardiovasc Electrophysiol 17[Suppl 3]: S2-S7, 2006.
21. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F: Cardiac consequences of hypertension in hemodialysis patients. Semin Dial 17: 299-303, 2004.
22. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4 [Suppl 1]: S79-S91, 2009.
23. Eloot S, Van Biesen W, Dhondt A, Van de Wynkele H, Glorieux G, Verdonck P, Vanholder R: Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 73: 765-770, 2008.
24. McFarlane PA: Nocturnal hemodialysis: Effects on solute clearance, quality of life, and patient survival. Curr Opin Nephrol Hypertens 20: 182-188, 2011.
25. Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG: Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis 43: 85-89, 2004.
26. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S: Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109: 3050-3055, 2004.
27. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, Dart A, Du XJ: Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 24: 1663-1670, 2006.
28. Siedlecki AM, Jin X, Muslin AJ: Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75: 800-808, 2009.
29. Sharpe N: Left ventricular remodeling: Pathophysiology and treatment. Heart Fail Monit 4: 55-61, 2003.
30. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM: The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J 155: 9-18, 2008.
31. Dialysis Outcomes and Practice Patterns Study: Achieved dialysis session length (minutes), by DOPPS country and crosssection. Available at: http://www.dopps.org/annualreport/html/qdialduration_TAB2010.htm. Accessed November 30, 2012.
32. Daugirdas JT: Is there a minimal amount of time a patient should be dialyzed regardless of measured KT/V? Semin Dial 24: 423-425, 2011